Probiotics supplementation in the management of hepatocellular carcinoma

Probiotics supplementation in the management of hepatocellular carcinoma

Ludovico Abenavoli1, Francesco Luzza1, Nahum Mendez-Sanchez2

1Department of Health Sciences, University Magna Graecia, Catanzaro, Italy; 2Liver Research Unit Medica Sur Clinic & Foundation and Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico

Correspondence to: Ludovico Abenavoli, MD, PhD. Department of Health Sciences, University “Magna Graecia”, Viale Europa, 88100, Catanzaro, Italy. Email:

Comment on: Wan MLY, El-Nezami H. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy. Hepatobiliary Surg Nutr 2018;7:11-20.

Submitted Sep 13, 2019. Accepted for publication Oct 10, 2019.

doi: 10.21037/hbsn.2019.10.12

Hepatocellular carcinoma (HCC, also known as primary liver cancer), is the fourth most frequent cancer and the third cause of deaths associated with cancer worldwide (1). HCC occurs in liver damaged tissue, due to chronic regenerative and inflammatory processes that contribute to the initiation and progression of the tumor (2). The main environmental factors associated with HCC are hepatotropic viral infection (hepatitis B and C, particularly), excessive consumption of alcohol, and exposure to aflatoxin through the diet. However, in the last 20 years, non-alcoholic fatty liver disease (NAFLD) has become a quickly emerging cause of end-stage liver disease worldwide. Typically, its hepatic injury starts with simple steatosis, which can progress to advanced stages such as non-alcoholic steatohepatitis (NASH), fibrosis and finally cirrhosis. Epidemiology studies report that about 3–15% of the obese patients with NASH progress to cirrhosis, and about 4–27% of NASH patients with cirrhosis present HCC (1).

Intestine and liver are strictly connected districts, as they are involved in nutrient absorption and metabolism. For this reason, is common to talk about the “gut-liver axis” (3,4), a connection that exposes directly the liver to gut-derived bacterial elements. In fact, portal blood flow transports to the liver products from gut, such as lipopolysaccharide (LPS), bacterial DNA and peptidoglycan (3). Actually, it has well established that human gastrointestinal tract, is an ecosystem also called microbiota, that contains up to 100 trillion of microbes of distinct taxonomy (2,000 different species) (4). Its composition varies in reason of multiple factors such as the type of delivery, gender, host age, geographic location, ethnicity, and alimentary regimen. In healthy people, the prevalent bacterial phyla are Firmicutes (30–50%), Bacteroidetes (20–40%) and Actinobacteria (1–10%). The intestinal microbiota, which is around 1–2 kg of our body weight, is an essential component of healthy body and it is involved in many functions such as producing vitamins, degrading bile acids, modulating immunity and even treating diseases, such as cancer (3,4).

Maintaining an equilibrium within the microbiota components is essential as a barrier against external environment. A disequilibrium of microbiota components, termed intestinal dysbiosis, impairs gut homeostasis and leads to overgrowth of certain detrimental bacteria involved in the onset of a variety of diseases. Increasing evidences suggest that the gut-liver axis can be involved in HCC development. In particular, endotoxemia produced by an unbalanced gut microbiota, may contribute to hepatocarcinogenesis (5). Probiotics are defined by United Nations and WHO as “live microorganisms which when administered in adequate amounts confer a health benefit for the host” (6). Probiotics are commensal bacteria, as a functional food ingredient able to modulate the gut microbiota with benefits to the human health. Strains of Lactobacillus and Bifidobacterium species are commonly used as probiotics in fermented dairy products. Emerging evidences indicates that probiotics may also be used as a therapeutic approach for HCC (7,8).

Particularly, it has been reported that gut microbial metabolites, as a lipoteichoic acids, elements of cell walls of gram-positive commensal bacteria, can induce the synthesis of prostaglandin E2 (PGE2) by hepatic stellate cells. PGE2 contrasts the antitumor activity of CD8+ T cells, and therefore acts indirectly as facilitator for the onset and development of HCC (9). It is also well known that the microbial metabolism of ursodeoxycholic acid, is necessary for the expression of its protective effects against colonic inflammation, and induces apoptosis of HCC cell lines in vitro (10). The gut microbiota modulation, may be the bridge between ursodeoxycholic acid bioactivity and anticancer effects.

Recently, Wan and El-Nezami discuss the interplay between the intestinal microbes and HCC, and the potential role of probiotics supplementation in the treatment of patients with HCC. The review was published in the month of February 2018 on HepatoBiliary Surgery and Nutrition (11). The Authors support the role of intestinal bacteria in liver carcinogenesis, and highlight the concept that the manipulation of gut microbiota may represent a novel approach in the prevention and treatment of HCC.

Many pathogenetic mechanisms, including leaky gut, endotoxemia, toll like receptors, small intestinal bacterial overgrowth (SIBO) and immunomodulation, promote the development of HCC. The digestive apparatus contributes to the immune homeostasis by maintaining an intact barrier against LPS and gut microbes (12). In case of increased intestinal permeability, bacterial translocation and LPS accumulation, will lead to intestinal bacterial overgrowth with consequent SIBO. In patients with advanced liver diseases, detoxification, degradation, and clearance of LPS and other bacterial products are altered. In the gut microbiota profile of cirrhotic patients with HCC, the increased fecal counts of Escherichia coli have been reported, in line with pre-clinical studies that report excess levels of Gram-negative bacteria as a Atopobium, Collinsella, Eggerthella, and Coriobacterium, with increased blood serum levels of LPS (7,13). To the contrary, it has been reported that microbiota of HCC patients contains low levels of Lactobacillus spp., Bifidobacterium spp., and Enterococcus spp., bacterial species that play a protective role against inflammatory diseases (13). In addition, two specific genera, Oribacterium and Fusobacterium are the most commonly isolated bacteria from tongue swab in these subjects, able to distinguish liver cancer patients from healthy subjects (14).

Probiotic mixtures demonstrated positive effect in in vivo studies on liver cancer. Antibiotic therapy has also been linked to decreased onset and progression of HCC in several preclinical studies. However, in this research area human data are lacking. It is also important to highlight that rifaximin, an eubiotic compound capable to induce overgrowth of beneficial gut bacteria, such as Bifidobacterium, Faecalibacterium, and Lactobacillus, and to induce an anti-inflammatory action, has never been tested in preclinical models of HCC (7). Rifaximin may represent a promising therapeutic approach, due to its capacity to contrasts the reduction of beneficial bacterial species reported during the development of HCC.

In the last decades, knowledge on the gut-liver axis has improved. Literature confirms that intestinal bacteria have a deep relationship with the liver, and play a significant role in the pathogenesis of hepatic injury, fibrosis progression, cirrhosis, and its complications, including HCC (15). Moreover, the exact mechanisms of this connection are still unclear. Our knowledge about the clinical significance of the use of probiotics in liver diseases, begins to take shape. On the basis of the discussed evidences, and in agreement with the Authors it is possible to conclude that, probiotics supplementation may be a safe and low-cost strategies in this context. However, more extensive human clinical trials to better understand the impact of microbiota-host interactions, the gut microbiota influence on health and to investigate the possible use of selected bacterial strains as a therapeutic option in the clinical management of HCC, are needed.




Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.


  1. Anstee QM, Reeves HL, Kotsiliti E, et al. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol 2019;16:411-28. [Crossref] [PubMed]
  2. Nakagawa H, Maeda S. Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J Gastroenterol 2012;18:4071-81. [Crossref] [PubMed]
  3. Preveden T, Scarpellini E, Milić N, et al. Gut microbiota changes and chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2017;11:813-19. [Crossref] [PubMed]
  4. Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. N Engl J Med 2016;375:2369-79. [Crossref] [PubMed]
  5. Yu LX, Yan HX, Liu Q, et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 2010;52:1322-33. [Crossref] [PubMed]
  6. Guidelines for the Evaluation of Probiotics in Food. Available online:
  7. Ponziani FR, Nicoletti A, Gasbarrini A, et al. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Ther Adv Med Oncol 2019;11:1758835919848184. [Crossref] [PubMed]
  8. Milosevic I, Vujovic A, Barac A, et al. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. Int J Mol Sci 2019. [Crossref] [PubMed]
  9. Loo TM, Kamachi F, Watanabe Y, et al. Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity. Cancer Discov 2017;7:522-38. [Crossref] [PubMed]
  10. Yamada S, Takashina Y, Watanabe M, et al. Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice. Oncotarget 2018;9:9925-39. [Crossref] [PubMed]
  11. Wan MLY, El-Nezami H. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy. Hepatobiliary Surg Nutr 2018;7:11-20. [Crossref] [PubMed]
  12. Man SM. Inflammasomes in the gastrointestinal tract: infection, cancer and gut microbiota homeostasis. Nat Rev Gastroenterol Hepatol 2018;15:721-37. [Crossref] [PubMed]
  13. Grąt M, Wronka KM, Krasnodębski M, et al. Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis. Transplant Proc 2016;48:1687-91. [Crossref] [PubMed]
  14. Lu H, Ren Z, Li A, et al. Tongue coating microbiome data distinguish patients with pancreatic head cancer from healthy controls. J Oral Microbiol 2019;11:1563409. [Crossref] [PubMed]
  15. Ramírez-Pérez O, Cruz-Ramón V, Chinchilla-López P, et al. The Role of the Gut Microbiota in Bile Acid Metabolism. Ann Hepatol 2017;16 Suppl 1:S21-6. [Crossref] [PubMed]
Cite this article as: Abenavoli L, Luzza F, Mendez-Sanchez N. Probiotics supplementation in the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr 2019;8(6):632-634. doi: 10.21037/hbsn.2019.10.12